Kezar Life Sciences (NASDAQ:KZR) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “

Separately, William Blair reaffirmed an outperform rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Kezar Life Sciences has a consensus rating of Buy and a consensus price target of $24.33.

Kezar Life Sciences stock opened at $7.15 on Wednesday. The company has a quick ratio of 21.81, a current ratio of 21.81 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average is $8.99. Kezar Life Sciences has a fifty-two week low of $6.10 and a fifty-two week high of $36.33.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.40) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.40). On average, research analysts anticipate that Kezar Life Sciences will post -2.04 EPS for the current year.

Several large investors have recently made changes to their positions in the company. FMR LLC grew its position in shares of Kezar Life Sciences by 12.6% in the fourth quarter. FMR LLC now owns 2,849,233 shares of the company’s stock valued at $67,242,000 after purchasing an additional 318,852 shares during the period. BlackRock Inc. grew its position in shares of Kezar Life Sciences by 1.9% in the fourth quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock valued at $5,804,000 after purchasing an additional 4,486 shares during the period. Geode Capital Management LLC grew its position in shares of Kezar Life Sciences by 126.7% in the fourth quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock valued at $1,369,000 after purchasing an additional 32,441 shares during the period. Northern Trust Corp grew its position in shares of Kezar Life Sciences by 8.7% in the fourth quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock valued at $1,345,000 after purchasing an additional 4,581 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Kezar Life Sciences in the first quarter valued at $704,000. 51.88% of the stock is owned by institutional investors and hedge funds.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.